|
|
Human skin permeation of emerging mycotoxins (beauvericin and enniatins)
|
|
|
|
|
نویسنده
|
Taevernier Lien ,Veryser Lieselotte ,Roche Nathalie ,Peremans Kathelijne ,Burvenich Christian ,Delesalle Catherine ,Spiegeleer Bart De
|
منبع
|
journal of exposure science and environmental epidemiology - 2016 - دوره : 26 - شماره : 3 - صفحه:277 -287
|
چکیده
|
Currently, dermal exposure data of cyclic depsipeptide mycotoxins are completely absent. there is a lack of understanding about the local skin and systemic kinetics and effects, despite their widespread skin contact and intrinsic hazard. therefore, we provide a quantitative characterisation of their dermal kinetics. the emerging mycotoxins enniatins (enns) and beauvericin (bea) were used as model compounds and their transdermal kinetics were quantitatively evaluated, using intact and damaged human skin in an in vitro franz diffusion cell set-up and ultra high-performance liquid chromatography (uhplc)-ms analytics. we demonstrated that all investigated mycotoxins are able to penetrate through the skin. enn b showed the highest permeation (kp,v=9.44 × 10−6 cm/h), whereas bea showed the lowest (kp,v=2.35 × 10−6 cm/h) and the other enns ranging in between. combining these values with experimentally determined solubility data, jmax values ranging from 0.02 to 0.35 μg/(cm2 h) for intact skin and from 0.07 to 1.11 μg/(cm2 h) for damaged skin were obtained. these were used to determine the daily dermal exposure (dde) in a worst-case scenario. on the other hand, dde’s for a typical occupational scenario were calculated based on real-life mycotoxin concentrations for the industrial exposure of food-related workers. in the latter case, for contact with intact human skin, dde’s up to 0.0870 ng/(kg bw × day) for enn a were calculated, whereas for impaired skin barrier this can even rise up to 0.3209 ng/(kg bw × day) for enn b1. this knowledge is needed for the risk assessment after skin exposure of contaminated food, feed, indoor surfaces and airborne particles with mycotoxins.
|
|
|
آدرس
|
Ghent University, Department of Pharmaceutical Analysis, Drug Quality and Registration (DruQuaR) Group, Belgium, Ghent University, Department of Pharmaceutical Analysis, Drug Quality and Registration (DruQuaR) Group, Belgium, University Hospital Ghent, Department of Plastic and Reconstructive Surgery, Belgium, Ghent University, Department of Medical Imaging and Small Animal Orthopaedics, Belgium, Ghent University, Department of Comparative Physiology and Biometrics, Belgium, Ghent University, Department of Comparative Physiology and Biometrics, Belgium, Ghent University, Department of Pharmaceutical Analysis, Drug Quality and Registration (DruQuaR) Group, Belgium
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Authors
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|